The Cannabist Company Reports New Partnership with Airo
Airo and The Cannabist Company have announced their new multi-state retail and wholesale partnership.
On November 21, 2023, The Cannabist Company, which is one of the biggest retailers, cultivators, and manufacturers located within the US, disclosed that they have formed a new partnership with Airo, a company that specializes in vaporizer products (1).
With this new partnership, The Cannabist Company will begin selling Airo’s inhalation brand products in their three Columbia Care dispensaries located in Delaware (1). According to a recent press release, The Cannabist Company will begin to list Airo’s products in their wholesale channels “in the coming weeks” (1). The Cannabist Company will also offer their new partner’s merchandise in their dispensary network within the next few months. This includes locations in Pennsylvania, West Virginia, and Virginia, pending regulatory approval (1).
“Airo is one of the most recognized and innovative vaporization brands, and we are thrilled to bring their high-performance vaporizers and unique oils into our dispensaries. Their products, which offer a consistent and intuitive experience, align perfectly with our mission to provide unmatched, superior quality for anyone who walks into our dispensaries,” Jesse Channon, The Cannabist Company’s Chief Commercial Officer, commented (1). “We are excited to bring these amazing products to additional markets as we continue to meet the expanding needs of our patients and customers as the cannabis industry grows and evolves.”
“We’re excited to be able to provide Delaware with our quality products and couldn’t have found a better partner than The Cannabist Company. The quality experience provided by their dispensaries are a great match with Airo,” said Richard Yost, CEO, Airo Brands (1).
Among their current merchandise line, Airo will be launching their new premium vapor systems and AiroPod cartridge oil formulations (1). The vapor systems will include the AiroSport, AiroX Disposable, and AiroPro. In regard to their cartridge oil formulations, Airo will be debuting Live Flower Series, Artisan Series, and their Strain Series. The company’s press release mentioned that the Strain Series will comprise of Northern Lights Indica, Cherry AK Sativa, and Blue Dream Hybrid (1). For Airo’s Artisan Series, they will carry Mystical Melody Hybrid, Midnight Moon Indica, and Black Mamba Sativa. Lastly, Airo’s Live Flower Series will include Lemon Jet Fuel Gelato Indica, Jack Fruit Sativa, and Gelonade Hybrid (1).
Reference
- The Cannabist Company Announces New Multi-State Retail and Wholesale Partnership with Leading Vaporizer Brand, Airo https://www.businesswire.com/news/home/20231121731537/en/The-Cannabist-Company-Announces-New-Multi-State-Retail-and-Wholesale-Partnership-with-Leading-Vaporizer-Brand-Airo (accessed Nov 21, 2023).
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
